Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

ClinicalTrials.gov ID: NCT00197145

Public ClinicalTrials.gov record NCT00197145. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Compare the Efficacy and Safety of GW873140 400mg BID in Combination With a Ritonavir-containing Optimized Background Therapy (OBT) Regimen Versus Placebo Plus OBT Over 48 Weeks.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety and efficacy of the CCR5 antagonist GW873140 or placebo in combination with an optimized background regimen in treatment-experienced HIV-infected subjects with R5-tropic virus

Study identification

NCT ID
NCT00197145
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
ViiV Healthcare
Industry
Enrollment
24 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 21, 2005 (Actual)
Primary completion
Sep 11, 2007 (Actual)
Completion
Sep 11, 2007 (Actual)
Last update posted
Nov 2, 2018

2005 – 2007

United States locations

U.S. sites
52
U.S. states
24
U.S. cities
46
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35294 —
GSK Investigational Site Beverly Hills California 90210 —
GSK Investigational Site Fountain Valley California 92708 —
GSK Investigational Site Laguna Beach California 92651 —
GSK Investigational Site Long Beach California 90813 —
GSK Investigational Site Los Angeles California 90046 —
GSK Investigational Site Los Angeles California 90069 —
GSK Investigational Site Oakland California 94609 —
GSK Investigational Site San Francisco California 94114 —
GSK Investigational Site Tarzana California 91356 —
GSK Investigational Site Glastonbury Connecticut 06033 —
GSK Investigational Site Norwalk Connecticut 06851 —
GSK Investigational Site Washington D.C. District of Columbia 20009 —
GSK Investigational Site Washington D.C. District of Columbia 20037 —
GSK Investigational Site Fort Lauderdale Florida 33306 —
GSK Investigational Site Fort Lauderdale Florida 33308 —
GSK Investigational Site Fort Myers Florida 33901 —
GSK Investigational Site Key West Florida 33040 —
GSK Investigational Site Miami Florida 33136 —
GSK Investigational Site Oakland Park Florida 33334 —
GSK Investigational Site Orlando Florida 32804 —
GSK Investigational Site Plantation Florida 33317 —
GSK Investigational Site Atlanta Georgia 30308/30309 —
GSK Investigational Site Atlanta Georgia 30339 —
GSK Investigational Site Decatur Georgia 30033 —
GSK Investigational Site Chicago Illinois 60613 —
GSK Investigational Site Chicago Illinois 60657 —
GSK Investigational Site Wichita Kansas 67214 —
GSK Investigational Site New Orleans Louisiana 70127-0800 —
GSK Investigational Site Portland Maine 04102 —
GSK Investigational Site Baltimore Maryland 21201 —
GSK Investigational Site Boston Massachusetts 02215 —
GSK Investigational Site Minneapolis Minnesota 55404 —
GSK Investigational Site St Louis Missouri 63108 —
GSK Investigational Site Las Vegas Nevada 89102 —
GSK Investigational Site East Orange New Jersey 07018 —
GSK Investigational Site Hillsborough New Jersey 08844 —
GSK Investigational Site Newark New Jersey 07102 —
GSK Investigational Site Mount Vernon New York 10550 —
GSK Investigational Site New York New York 10014 —
GSK Investigational Site Charlotte North Carolina 28209 —
GSK Investigational Site Akron Ohio 44304 —
GSK Investigational Site Portland Oregon 97209 —
GSK Investigational Site Portland Oregon 97219 —
GSK Investigational Site Columbia South Carolina 29206-4713 —
GSK Investigational Site Austin Texas 78746 —
GSK Investigational Site Dallas Texas 75246 —
GSK Investigational Site Houston Texas 77027 —
GSK Investigational Site Annandale Virginia 22003 —
GSK Investigational Site Hampton Virginia 23666 —
GSK Investigational Site Lynchburg Virginia 24501 —
GSK Investigational Site Spokane Washington 99204 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00197145, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 2, 2018 · Synced Oct 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00197145 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →